SPEAC has completed a fifth update to the Priority List of potential Adverse events of special interest relevant to COVID-19 vaccine trials. Past updates focused on COVID-19 disease course and complications whereas this one shifts the emphasis to what has been observed for COVID-19 vaccines currently in use. It is limited to countries with pharmacovigilance programs in place that are able to monitor large populations (United States, Canada, Australia, United Kingdom, European Union).
http:brightoncollaboration.org/wp-content/uploads/2023/08/Updated-COVID-19-AESI-list_Oct2022-1.pdf
